Clinical Trial

Immunoprevention for High-risk Lung Lesions

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-08; most recent amendment 2026-06-05.
Status change: Not Yet Recruiting → Recruiting 2026-03-06
Trial Details
NCT Number NCT07284485
Lead Sponsor Robert Samstein
Collaborators: Cantargia AB
Conditions High-risk Lung Nodules
Enrollment 59 participants
Start Date 2026-05-21
Primary Completion 2027-12-15 (estimated)
Study Completion 2029-12-17 (estimated)
Updated on ClinicalTrials.gov 2026-06-08